Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer
Status:
Recruiting
Trial end date:
2024-06-20
Target enrollment:
Participant gender:
Summary
Peritoneal metastasis is a major pattern of gastric cancer recurrence and predicts poor
prognosis. In our previous study, we developed a next-generation sequencing technology to
detect minimal residual cancer cells in peritoneal lavage fluid with a personalized assay
profiling tumor-specific mutations in patients with gastric cancer. With this technology, we
predicted all the cases that developed peritoneal metastasis in patients with pT4 disease
with 100% sensitivity and 91% specificity. Based on this result, a prospective phase 2
clinical trial is designed to evaluate the efficacy of adjuvant intraperitoneal chemotherapy
in patients with positive cancer cell DNA detected in peritoneal lavage fluid by our
personalized tumor-specific mutation profiling assay.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences